Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2018, Article ID 5284963, 11 pages
Research Article

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling

1Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria
2Department of Cardiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
3DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada
5Department of Internal Medicine V, Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria
6Department of Cardiology, Reha Zentrum Muenster, Münster, Tirol, Austria

Correspondence should be addressed to Christoph Brenner; ten.rennerbc.dem@liam

Received 17 August 2017; Revised 23 November 2017; Accepted 2 December 2017; Published 8 February 2018

Academic Editor: Mingfu Wu

Copyright © 2018 Friederike Remm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [4 citations]

The following is the list of published articles that have cited the current article.

  • Matthias Kolibabka, Nadine Dietrich, Thomas Klein, and Hans-Peter Hammes, “Anti-angiogenic effects of the DPP-4 inhibitor linagliptin via inhibition of VEGFR signalling in the mouse model of oxygen-induced retinopathy,” Diabetologia, 2018. View at Publisher · View at Google Scholar
  • Yi Zhou, Zhiying Guo, Wenjing Yan, and Wen Wang, “Cardiovascular effects of sitagliptin - An anti-diabetes medicine,” Clinical and Experimental Pharmacology and Physiology, 2018. View at Publisher · View at Google Scholar
  • Srinivasan Vedantham, Anna-Kristina Kluever, and Elisabeth Deindl, “Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review,” Cells, vol. 7, no. 10, pp. 181, 2018. View at Publisher · View at Google Scholar
  • Takamasa Iwakura, Zhibo Zhao, Julian A Marschner, Satish Kumar Devarapu, Hideo Yasuda, and Hans Joachim Anders, “Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration,” Nephrology Dialysis Transplantation, 2019. View at Publisher · View at Google Scholar